Evidence map›Paper›PMID 38451572›Full record

ArticleRevista da Associacao Medica Brasileira (1992)2024

Predicting the outcome of death by CALL Score in COVID-19 patients.

Marcus Villander Barros de Oliveira Sá, Clarice Neuenschwander Lins de Morais, Rafaela Silva Guimarães Gonçalves, Camila Sarteschi, Luydson Richardson Silva Vasconcelos

Abstract read
In one paragraph

Article in Revista da Associacao Medica Brasileira (1992), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marcus Villander Barros de Oliveira SáRoyal Portuguese Charitable Hospital, Royal Medical Clinic - Recife (PE), Brazil.ORCID http://orcid.org/0000-0003-1257-6958
Clarice Neuenschwander Lins de MoraisAggeu Magalhães Institute, Oswaldo Cruz Foundation, Department of Parasitology and Immunology - Recife (PE), Brazil.ORCID http://orcid.org/0000-0002-0887-8163
Rafaela Silva Guimarães GonçalvesUniversidade Federal de Pernambuco, Clinical Hospital - Recife (PE), Brazil.ORCID http://orcid.org/0000-0001-9014-6529
Camila SarteschiRoyal Portuguese Charitable Hospital, Royal Medical Clinic - Recife (PE), Brazil.ORCID http://orcid.org/0000-0001-8536-0598
Luydson Richardson Silva VasconcelosAggeu Magalhães Institute, Oswaldo Cruz Foundation, Department of Parasitology and Immunology - Recife (PE), Brazil.ORCID http://orcid.org/0000-0002-1625-3358

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to assess the performance of the CALL Score tool in predicting the death outcome in COVID-19 patients.

methodsA total of 897 patients were analyzed. Univariate and multivariate logistic regression analyses were conducted to determine the association between characteristics of the CALL Score and the occurrence of death. The relationship between CALL Score risk classification and the occurrence of death was also examined. Receiver operating characteristic curve analysis was performed to identify optimal cutoff points for the CALL Score and the outcome.

resultsThe study revealed that age>60 years, DHL>500, and lymphocyte count ≤1000 emerged as independent predictors of death. Higher risk classifications of the CALL Score were associated with an increased likelihood of death. The optimal CALL Score cutoff point for predicting the death outcome was 9.5 (≥9.5), with a sensitivity of 70.4%, specificity of 80.3%, and accuracy of 80%.

conclusionThe CALL Score showed promising discriminatory ability for death outcomes in COVID-19 patients. Age, DHL level, and lymphocyte count were identified as independent predictors. Further validation and external evaluation are necessary to establish the robustness and generalizability of the CALL Score in diverse clinical settings.

Indexed as

COVID-19HumansLymphocyte CountMiddle AgedPatientsROC Curve

Identifiers

PMID38451572
PMCPMC10913782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.